Experimental skin necrosis produced by adriamycin.

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Extravasation of Adriamycin (chemotherapy drug) leads to severe, prolonged skin ulceration and morbidity.
• Developing a reliable animal model is crucial for studying and mitigating Adriamycin-induced skin injury.

Purpose of the Study:

• To establish a reproducible animal model for Adriamycin-induced skin ulceration.
• To investigate the relationship between Adriamycin concentration, volume, and the severity of skin necrosis and healing time.

Main Methods:

• Comparison of intradermal versus subcutaneous panniculus carnosus injections of Adriamycin in rats.
• Varying drug volumes and concentrations to assess impact on ulcer size and healing.
• Histological examination of affected skin tissue.

Main Results:

• Intradermal Adriamycin injection produced predictable, uniform skin necrosis and ulceration, unlike subcutaneous injections.
• Increased Adriamycin volume and concentration proportionally increased ulcer size and delayed healing.
• A critical concentration range for necrosis was identified between 0.010–0.020 mg/ml.
• Adriamycin-induced necrosis healed slower than surgical defects, with delayed wound contraction.
• Histology revealed early necrosis, inflammation after one week, epidermal hypertrophy, patent vessels, and dermal vesicles.

Conclusions:

• Intradermal injection of Adriamycin in rats provides a suitable model for studying chemotherapy-induced skin ulceration.
• Drug concentration is a critical factor in Adriamycin-induced skin necrosis, suggesting dilution strategies may reduce clinical complications.
• Understanding the healing dynamics, including reduced wound contraction, is important for managing these injuries.